Skip to main content
  • English
  • Français
  • About Us
    • About Us
    • Our Purpose and Identity
    • Integrated Report 2021
    • Governance
      • Governance
      • Board of Directors
      • Executive Committee
    • Where we are
    • Through time
    • All Our Stories
      • All Our Stories
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
  • Your Health
    • Your Health
    • Health and Well-Being
    • Diabetes and Cardiovascular Diseases
    • Specialty Care
      • Specialty Care
      • Rare Diseases
      • Rare Blood Disorders
      • Neurology
      • Immunology
      • Oncology
        • Oncology
        • When Cancer Grows Old
          • When Cancer Grows Old
          • Contributions Initiative
          • Global collaboration
      • Patient Support
    • Vaccines
      • Vaccines
      • The Value of vaccines
      • How immunization works
      • Infectious Disease and Vaccines
        • Infectious Disease and Vaccines
        • COVID-19
        • Influenza
        • Meningococcal Meningitis
        • Pertussis
        • Poliomyelitis
        • Respiratory Syncytial Virus
        • Discover more
      • Research and Innovation
      • Vaccines Production
      • Vaccines Stories
  • Science & Innovation
    • Science & Innovation
    • Partnering
      • Partnering
      • Let's partner
      • Areas of Interest
        • Areas of Interest
        • China & Emerging Markets
        • Digital
        • General Medicines
        • Immunology
        • Neuroscience
        • Oncology
        • Out-Licensing
        • Rare Diseases
        • Technology Platforms
        • Vaccines
      • Meet the team
    • Research & Development
      • Research & Development
      • Sanofi Pipeline
      • Vaccines
      • Immunology and Inflammation
      • Neurology
      • Oncology
      • Pioneering Technology Platforms
        • Pioneering Technology Platforms
        • Genomic Medicine Technology Platform
        • mRNA Technology: Vaccines and Beyond
        • NANOBODY® Technology Platform
        • SYNTHORIN™ Technology Platform
      • Rare Blood Disorders R&D
      • Rare Diseases
      • Voices from the Lab
    • Clinical Trials & Results
      • Clinical Trials & Results
      • Phases
      • Our disclosure commitments
        • Our disclosure commitments
        • Sanofi Pharma
        • Sanofi Genzyme
        • Sanofi Pasteur
      • Our data sharing commitments
      • Managed Access Programs (MAPs)
      • Investigator Sponsored Studies and Externally Sponsored Collaboration
    • Collaboration & Awards
      • Collaboration & Awards
      • Europe
        • Europe
        • iAwards
        • iDEA-iTECH
      • North America
        • North America
        • iAwards
        • iDEA-iTECH
      • China
    • Science Stories
  • Our Responsibility
    • Our Responsibility
    • Access to Quality Healthcare – Sanofi Global Health
    • Environmental sustainability
    • Diversity, Equity and Inclusion
      • Diversity, Equity and Inclusion
      • Making an Impact
      • Board & Employee Groups
      • Gender Balance
        • Gender Balance
        • Women@Sanofi
      • Our Partners
      • Our LGBTQ+ Voice
    • Healthcare for all
      • Healthcare for all
      • Sanofi Humanitarian Aid Programs
      • Contributing to the eradication, elimination and control of some infectious diseases
      • Fighting Against Falsified Medicine
      • Serving the needs of patients with non-communicable diseases
    • Corporate Citizenship
    • Foundation S (Endowment Fund)
    • Ethics & Transparency
      • Ethics & Transparency
      • Code of Ethics
    • Suppliers
    • Document center
      • Document center
      • All factsheets
      • Access to Healthcare and Pricing
      • Country reports and other documents
      • CSR Strategy and Value Creation
      • Duty of Vigilance incl. Supply Chain
      • Environment
      • Ethics and Transparency
      • Governance, Controls and Procedures
      • Reporting Frameworks and Indicators
      • Social incl. Communities
  • |
  • Careers
    • Careers
    • Explore our career opportunities
    • A range of possibilities
      • A range of possibilities
      • Market access
      • Marketing
      • Medical
      • Production
      • Research & Development
      • Consumer Healthcare
      • Vaccines careers
      • Student / Graduate / Young Professionals
      • Discover more possibilities
    • Grow with us
      • Grow with us
      • Diversity & Inclusion
      • Development opportunity: how Sanofi empowers you
      • Benefits
  • Investors
    • Investors
    • Company overview
      • Company overview
      • Sanofi at a glance
      • Strategy
      • Environmental, Social, Governance
      • Financial reporting center & Key data
      • Fixed income
    • Financial results and events
      • Financial results and events
      • Financial calendar
      • Quarterly earnings at a glance
      • Investor presentations
        • Investor presentations
        • Capital Markets Day on Euroapi
      • Annual General Meetings
      • Broker conferences
    • Sanofi share and ADRs
      • Sanofi share and ADRs
      • Share overview
        • Share overview
        • Shares & voting rights
        • Share repurchases
      • Sanofi stock chart
      • Shareholding calculator
      • Dividends
      • ADRs
      • Shareholding structure
      • Vara consensus
    • Corporate governance
      • Corporate governance
      • Governance
      • Board of Directors
      • Executive Committee
      • Specialist committees
      • Compensations
      • Standards & rules
      • Regulated agreements
      • Internal Control
    • Individual Shareholders
      • Individual Shareholders
      • Welcome to Sanofi
      • Being a shareholder
        • Being a shareholder
        • How to buy Sanofi shares
        • Registered shares
      • Shareholder events
        • Shareholder events
        • Financial Calendar
        • Annual General Meetings
        • Participate in General Meetings
      • Reports and publications
        • Reports and publications
        • Financial and CSR reports
        • Shareholder publications
      • Shareholders committee
    • Reports and publications
      • Reports and publications
      • Financial and CSR reports
      • Shareholder publications
    • Regulated information
    • Contacts
  • Media
    • Media
    • Press releases
      • Press releases
      • 2022
        • 2022
        • Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer
        • Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
        • Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma
        • Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
        • Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
        • Sanofi recognized by S&P as one of the most sustainability-committed companies
        • Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
        • Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
        • Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
        • Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
        • Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
        • Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
        • Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
        • Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
        • Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence
        • FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
        • Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
        • Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD
        • Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
        • Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
        • Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
        • Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
        • Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
        • Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants
        • Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
        • Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer
        • Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
        • Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
        • Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
        • Availability of the Q4 2021 Memorandum for modelling purposes
        • New preclinical tolebrutinib data demonstrated superior brain penetration and potency
        • Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
        • Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
        • Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
        • Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
        • Nexviazyme® (avalglucosidase alfa) shows sustained improvements in respiratory function and mobility in patients with Pompe disease
        • CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
        • Sanofi completes acquisition of Amunix
        • Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
        • FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
        • Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
        • Media Update: Rezurock® (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease
        • Press Release: Annual General Meeting of May 3, 2022
        • Press Release: Foundation S: Sanofi’s new philanthropic spearhead
        • Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial
        • Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
        • Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
        • Press Release: New nirsevimab data analyses reinforce efficacy against RSV
        • Press Release: Annual General Meeting of May 3, 2022
        • Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
        • Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting
        • Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)
        • Media Update: CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD
        • Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
        • Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
        • Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
        • Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
        • Media Update: Sanofi, a leader in immune-mediated rare blood disorders, to present latest data at EHA 2022
        • Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
        • Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
        • Availability of the Q2 2022 Memorandum for modelling purposes
        • Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older
        • Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
        • Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
        • Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.
        • Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
        • Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
        • Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
        • Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
        • Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
        • Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
        • Media Update: Tolebrutinib clinical trial program update
        • Sanofi Media Update
        • Press Release: Sanofi provides update on amcenestrant clinical development program
        • Media Update: New Dupixent® (dupilumab) data at ERS adds to body of safety and efficacy data in chronic respiratory diseases
        • Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A
        • Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
        • Press Release: Evolution of the Board of Directors
        • Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
        • Media Update: New Dupixent® (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases
        • Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
        • Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet
        • Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
        • Media Update: CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease
        • Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
        • Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
      • 2021
        • 2021
        • Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma
        • Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
        • Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
        • Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
        • New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
        • Sanofi completes acquisition of Kadmon
        • Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
        • Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
        • Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
        • Sanofi announces results of CHMP re-examination of the New Active Substance status for avalglucosidase alfa, a potential new standard of care for the treatment of Pompe disease
        • Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
        • EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD
        • Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
        • Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
        • Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
        • Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
        • Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
        • Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
        • ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
        • Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
        • Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021
        • Sanofi continues streamlining of established products with sale of dental care brands to Septodont
        • Sanofi launches its new global employee share ownership plan
        • Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
        • MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers
        • Libtayo® (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers
        • Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
        • Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
        • Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine
        • European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
        • FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
        • Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
        • New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
        • Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
        • Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
        • Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
        • Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
        • New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 
        • Sanofi provides update on Aubagio® (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.
        • Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
        • FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
        • Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
        • Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
        • Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
        • New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia  
        • New Soliqua® data shows improved blood sugar control without weight gain versus premixed insulin
        • Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
        • Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress
        • Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
        • Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
        • Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients  
        • Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
        • New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
        • Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma
        • Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris
        • New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection
        • Sanofi launches dedicated vaccines mRNA Center of Excellence
        • Sanofi provides update on venglustat clinical program
        • Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
        • Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
        • Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA
        • Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI
        • Sanofi to acquire Kadmon to further strengthen growth of transplant business
        • US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness
        • New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021
        • Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings
        • Sanofi provides update on avalglucosidase alfa EU submission for patients with Pompe Disease
        • Online availability of Sanofi’s half-year financial report for 2021
        • Sales growth accelerated - Full-year guidance raised
        • Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
        • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
        • Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
        • Sanofi declares the offer for Kiadis unconditional
        • New indication for Plavix® (clopidogrel) now approved in the European Union
        • Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
        • Positive Phase 3 Libtayo® (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary
        • Delisting of Kiadis will be effective on 25 May 2021
        • European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
        • Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
        • Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021
        • FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
        • CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma
        • FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
        • Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs
        • Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
        • New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders
        • Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
        • Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
        • Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands
        • Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
        • FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
        • Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine
        • Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
        • Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
        • Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
        •  Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease
        • Sanofi completes Kymab acquisition
        • Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
        • Sanofi completes Kiadis acquisition
        • Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
        • Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
        • SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
        • Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
        • Annual General Meeting of April 30, 2021
        • Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
        • Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici
        • Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
        • New Dupixent® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting
        • Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A
        • Availability of the Q1 2021 Memorandum for modelling purposes
        • Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V.
        • Sanofi launches recommended cash offer for all shares in Kiadis
        • The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
        • FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
        • Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
        • Kiadis shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
        • New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
        • Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
      • 2020
        • 2020
        • Sanofi and Kiadis satisfy competition condition related to the tender offer
        • Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
        • Update on the intended offer by Sanofi for Kiadis
        • CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
        • Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
        • Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
        • FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
        • Sanofi to resume dosing in fitusiran clinical studies in the U.S.
        • Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
        • European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
        • FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
        • Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
        • Availability of the Q4 2020 Memorandum for modelling purposes
        • European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
        • Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
        • Availability of the Pre-quarterly Results Communication
        • Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease
        • FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
        • Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
        • Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
        • Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
        • Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
        • Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease
        • Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union
        • Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
        • CHMP recommends approval of MenQuadfi® for active immunization of individuals from the age of 12 months and older against invasive meningococcal ACWY disease
        • Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
        • Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan
        • Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
        • Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
        • EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
        • Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
        • CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
        • Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
        • Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
        • New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
        • European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma
        • Sanofi completes Principia Biopharma Inc. acquisition
        • Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
        • Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
        • Sanofi offers to acquire Kiadis for €308 million
        • Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
        • Sanofi invests to make France its world class center of excellence in vaccine research and production
        • Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
        • Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
        • Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
        • Sanofi announces closing of Regeneron stock sale
        • New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020
        • Safety and efficacy of Dupixent® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis further reinforced by new data analyses presented at EADV
        • Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
        • Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases
        • CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
        • European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
        • Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
        • Online availability of Sanofi’s half-year financial report for 2020
        • Sanofi to acquire Principia Biopharma
        • Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
        • Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
        • Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors 
        • Availability of the Q3 2020 Memorandum for modelling purposes
        • Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
        • Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
        • Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial
        • Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline
        • Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
        • Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
        • COVID-19:  Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries 
        • Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
        • Sanofi : Availability of the Pre-quarterly Results Communication
        • Sanofi announces pricing of Regeneron stock offering
        • Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
        • Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine
        • Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
        • Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis
        • Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
        • Sanofi: Annual General Meeting of April 28, 2020
        • Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma
        • Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors
        • Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event
        • Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
        • Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
        • Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
        • Sanofi names new leaders to Executive Committee
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis
        • Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
        • FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination
        • Sanofi successfully prices EUR 1.5 billion of bond issue
        • Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
        • Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
        • Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
        • Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
        • Sanofi successfully prices taps on outstanding bond issues for EUR 500 million
        • Sanofi: Information on Sanofi’s Shareholder General Meeting of Tuesday, April 28, 2020
        • Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma
        • Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director
        • FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease
        • Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
        • Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
        • Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution
        • Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron
        • Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
        • Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)
        • Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis
        • Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.
        • Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx
      • 2019
        • 2019
        • Sanofi commences tender offer for acquisition of Synthorx, Inc.
        • Sanofi Q3 well on track
        • Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
        • Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
        • Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
        • Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
        • Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
        • Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
        • Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
        • Sanofi CEO unveils new strategy to drive innovation and growth
        • Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
        • Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
        • Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
        • Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
        • Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
        • Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
        • Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
        • Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
        • Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
        • Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
        • Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
        • Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
        • Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
        • Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
        • Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
        • Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
        • CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
        • Sanofi appoints Ameet Nathwani Chief Digital Officer
        • Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
        • Sanofi : CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
        • Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
        • Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
        • Sanofi: Annual General Meeting of April 30, 2019
        • Sanofi : Availability of the Pre-quarterly Results Communication
        • Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
        • Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
        • Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
        • Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
        • Sanofi and Google to develop new healthcare Innovation Lab
        • Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019
        • Sanofi successfully prices EUR 2 billion of bond issues
        • Sanofi : Availability of the Pre-quarterly Results Communication
        • Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
        • Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
        • Sanofi delivered solid growth in Q2 2019
        • Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
        • Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
        • Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
        • Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
        • Sanofi delivers 2018 business EPS growth of 5.1% at CER
        • Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
        • Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
        • Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
        • Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
        • Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
        • Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
        • New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
        • Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
      • 2018
        • 2018
        • Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1
        • FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
        • Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
        • Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
        • Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer
        • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
        • Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva
        • Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
        • Sanofi : Sanofi successfully prices USD 2 billion bond issue
        • Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
        • Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes
        • Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
        • Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
        • FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
        • Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
        • Sanofi successfully prices EUR 8 billion of bond issues
        • Online Availability of Sanofi Group's Half-Year Financial Report for 2018
        • Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018
        • Sanofi reaches civil settlement with US SEC
        • New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
        • Sanofi Q3 2018 Performance Confirms Return to Growth
        • Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
        • Sanofi to invest €350 million in Canadian vaccine facility
        • Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
        • Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
        • Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
        • Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
        • Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER
        • Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
        • Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab)
        • Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • Sanofi to refocus two global business units
        • Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business
        • Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
        • Sanofi: Annual General Shareholders' Meeting of May 2, 2018
        • Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan
        • Sanofi completes divestiture of Zentiva to Advent
        • Dengvaxia® vaccine approved for prevention of dengue in Europe
        • Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
        • Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st
        • Sanofi receives positive CHMP opinion for dengue vaccine
        • Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
        • Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
        • Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
        • Sanofi: Availability of the Pre-quarterly Results Communication
        • Sanofi to acquire Ablynx for €3.9 Billion
        • Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx
        • Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
        • Sanofi Completes Acquisition of Bioverativ Inc.
        • Sanofi Delivers 2017 Business EPS(1) in line with Guidance
        • Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ
        • Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
        • Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
        • Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
        • Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
        • 2018-01-29-08-43-24-1313336
        • Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
        • Sanofi to Acquire Bioverativ for $11.6 Billion
        • Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
        • Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
        • Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
        • Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
        • Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
    • Articles
      • Articles
      • 2019
    • Contacts
    • Media Alert
Worldwide
EN
  • EN
  • FR

INVESTORS

Inside information

  • Home
  • Investors
  • Regulated information
  • inside-information
  • 2020-12-11: Press Release
  • 2019-12-09: Press Release
Sanofi

    Follow us

  • Contact
  • Legal notice
  • Privacy & Data Protection
  • Cookies policy
  • Corporate code of ethics
  • Our publications
  • Sitemap
  • Our websites
  • Accessibility: partial compliance

© Sanofi 2004-2022 - All rights reserved

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED